Semaglutide May Be Better If You: Want a medication with longer track record and more research Prefer having the option of pills instead of injections Have diabetes and need proven heart benefits Experience fewer side effects with single-hormone approach Semaglutide has proven cardiovascular benefits and can reduce the risk of heart attack and stroke in people with diabetes
This means qualified pharmacies can still compound these products until these drugs are removed from the FDAs drug shortage list
Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves lean mass and enhances fat loss, offering a potential advancement in obesity treatment
The drug is an oral selective oestrogen receptor degrader or SERD, and there are two approved drugs in this class in the EU Menarini/Stemline's Orserdu (elacestrant) and Eli Lilly's Inluriyo (imlunestrant) which are both approved for second-line use in patients with this form of breast cancer
Sources Food and Drug Administration (FDA): FDA Approves New Medication for Chronic Weight Management Molecular Metabolism Journal: Glucagon-like peptide 1 (GLP-1) American Gastroenterological Association (AGA): Biology of Incretins: GLP-1 and GIP Columbia Surgery: The Ozempic Effect: Everything You Need to Know About Medical Weight Loss Eli Lilly: Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies American Diabetes Association (ADA): Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes Important Medical Information and Disclaimers Important Current Status Update : As of March 19, 2025, the FDA has ended enforcement discretion for compounded tirzepatide
